GHRP-2

Also known as: Pralmorelin, GH-releasing peptide 2

Evidence Tier Bhigh riskintermediatenot approved

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

GH Axis

This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.

Overview

GHRP-2 (pralmorelin) is a GH secretagogue that stimulates GH release. Human studies report IV doses in the 1-2 Âµg/kg range comparing GH/PRL/ACTH/cortisol responses in young and elderly cohorts. Also used in diagnostic GH stimulation testing in some regions. Endocrine spillover to ACTH/cortisol/prolactin is a meaningful risk.

Research Details

Mechanism of Action

GH secretagogue stimulating GH release; endocrine spillover to ACTH/cortisol/prolactin studied.

Study Dose Range

Human: IV 1-2 Âµg/kg in stimulation test protocols.

Administration Routes

intravenous, subcutaneous

Onset / Timeline

Acute hormone response within minutes to hours in stimulation tests.

Expected Effects

GH-axis stimulation; diagnostic use in some clinical settings.

Adverse Effects

Endocrine spillover (ACTH, cortisol, prolactin); glucose metabolism concerns.

Contraindications

No formal label (not approved for consumer use).

Interaction Notes

Endocrine spillover risks; avoid 'safe GH boost' framing.

Related Goals

Muscle Growth & StrengthFat Loss & MetabolismGH Axis Optimization

Known Interactions

caution with CJC-1295

Additive GH-axis stimulation plausible (mechanistic); conservative gating.

caution with Sermorelin

GHRH analog + GHS-R agonist: additive GH release plausible.

caution with Ipamorelin

Multiple GHS/GHS-R stimulation; limited stacking safety evidence.

caution with GHRP-6

Multiple GHS/GHS-R stimulation; higher uncertainty.

caution with MK-677

Multiple ghrelin-receptor secretagogues in one stack increase endocrine noise and monitoring needs.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Sermorelin

GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.